Cancer treatment and survivorship statistics, 2012

被引:690
作者
Siegel, Rebecca [1 ]
DeSantis, Carol
Virgo, Katherine
Stein, Kevin [1 ]
Mariotto, Angela
Smith, Tenbroeck [1 ]
Cooper, Dexter [1 ]
Gansler, Ted
Lerro, Catherine
Fedewa, Stacey
Lin, Chunchieh
Leach, Corinne [1 ]
Cannady, Rachel Spillers [1 ]
Cho, Hyunsoon [2 ]
Scoppa, Steve [3 ]
Hachey, Mark [3 ]
Kirch, Rebecca
Jemal, Ahmedin
Ward, Elizabeth
机构
[1] Amer Canc Soc, Behav Res Ctr, Atlanta, GA 30303 USA
[2] NCI, Data Modeling Branch, Surveillance Res Program, Div Canc Control & Populat Sci, Bethesda, MD 20892 USA
[3] Informat Management Serv Inc, Silver Spring, MD USA
关键词
QUALITY-OF-LIFE; LONG-TERM SURVIVORS; ANDROGEN DEPRIVATION THERAPY; ACUTE-LYMPHOBLASTIC-LEUKEMIA; SUPERFICIAL BLADDER-CANCER; HEALTHY FOOD CHOICES; BREAST-CANCER; UNITED-STATES; PROSTATE-CANCER; ADJUVANT CHEMOTHERAPY;
D O I
10.3322/caac.21149
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Although there has been considerable progress in reducing cancer incidence in the United States, the number of cancer survivors continues to increase due to the aging and growth of the population and improvements in survival rates. As a result, it is increasingly important to understand the unique medical and psychosocial needs of survivors and be aware of resources that can assist patients, caregivers, and health care providers in navigating the various phases of cancer survivorship. To highlight the challenges and opportunities to serve these survivors, the American Cancer Society and the National Cancer Institute estimated the prevalence of cancer survivors on January 1, 2012 and January 1, 2022, by cancer site. Data from Surveillance, Epidemiology, and End Results (SEER) registries were used to describe median age and stage at diagnosis and survival; data from the National Cancer Data Base and the SEER-Medicare Database were used to describe patterns of cancer treatment. An estimated 13.7 million Americans with a history of cancer were alive on January 1, 2012, and by January 1, 2022, that number will increase to nearly 18 million. The 3 most prevalent cancers among males are prostate (43%), colorectal (9%), and melanoma of the skin (7%), and those among females are breast (41%), uterine corpus (8%), and colorectal (8%). This article summarizes common cancer treatments, survival rates, and posttreatment concerns and introduces the new National Cancer Survivorship Resource Center, which has engaged more than 100 volunteer survivorship experts nationwide to develop tools for cancer survivors, caregivers, health care professionals, advocates, and policy makers. CA Cancer J Clin 2012. Published 2012 American Cancer Society.
引用
收藏
页码:220 / 241
页数:22
相关论文
共 197 条
[61]  
Fashoyin-Aje LA, 2012, J SUPPORT ONCOL
[62]   Association of Insurance and Race/Ethnicity with Disease Severity among Men Diagnosed with Prostate Cancer, National Cancer Database 2004-2006 [J].
Fedewa, Stacey A. ;
Etzioni, Ruth ;
Flanders, W. Dana ;
Jemal, Ahmedin ;
Ward, Elizabeth M. .
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2010, 19 (10) :2437-2444
[63]   Delays in Adjuvant Chemotherapy Treatment Among Patients With Breast Cancer Are More Likely in African American and Hispanic Populations: A National Cohort Study 2004-2006 [J].
Fedewa, Stacey A. ;
Ward, Elizabeth M. ;
Stewart, Andrew K. ;
Edge, Stephen B. .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (27) :4135-4141
[64]  
Ferrell B R, 1997, Oncology (Williston Park), V11, P565
[65]  
FERRELL BR, 1997, ONCOLOGY WILLISTON P, V11, P575
[66]  
FERRELL BR, 1997, ONCOLOGY WILLISTON P, V11, P572
[67]   Fatigue, anxiety, and depression in long-term survivors of testicular cancer [J].
Fossa, SD ;
Dahl, AA ;
Loge, JH .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (07) :1249-1254
[68]  
Freedman DM, 2006, NIH PUBL, V05-5302, P339
[69]   Quality of life and sexual functioning in cervical cancer survivors [J].
Frumovitz, M ;
Sun, CC ;
Schover, LR ;
Munsell, MF ;
Jhingran, A ;
Wharton, JT ;
Eifel, P ;
Bevers, TB ;
Levenback, CF ;
Gershenson, DM ;
Bodurka, DC .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (30) :7428-7436
[70]   Analysis of HER2 and HER4 in human myocardium to clarify the cardiotoxicity of trastuzumab (Herceptin™) [J].
Fuchs, IB ;
Landt, S ;
Bueler, H ;
Kuehl, U ;
Coupland, S ;
Kleine-Tebbe, A ;
Lichtenegger, W ;
Schaller, G .
BREAST CANCER RESEARCH AND TREATMENT, 2003, 82 (01) :23-28